Tainuo Meibok Board IPO has been "inquired" and the core product Stedutta single agent injection has been approved for listing in China in February this year.

According to the financial news app "Zhitong Finance", on August 11th, Zhuhai Tianomabo Pharmaceutical Co., Ltd. (referred to as Tianomabo) has changed its status from "under review" to "currently under inquiry" for listing on the Shanghai Stock Exchange's Sci-Tech Innovation Board. Huatai United Securities is the sponsor institution, and the company plans to raise 1.5 billion yuan.